Quantitative real-time reverse-transcription polymerase chain reaction for diagnosis of BCR-ABL positive leukemias and molecular monitoring following allogeneic stem cell transplantation

被引:26
作者
Neumann, F
Herold, C
Hildebrandt, B
Kobbe, G
Aivado, M
Rong, A
Free, M
Rössig, R
Fenk, R
Schneider, P
Gattermann, N
Royer-Pokora, B
Haas, R
Kronenwett, R
机构
[1] Univ Dusseldorf, Dept Hematol Oncol & Clin Immunol, D-40225 Dusseldorf, Germany
[2] Univ Dusseldorf, Inst Human Genet & Anthropol, D-40225 Dusseldorf, Germany
关键词
chronic myelogenous leukemia; molecular monitoring; real-time quantitative polymerase chain reaction; chimerism; allogeneic transplantation;
D O I
10.1034/j.1600-0609.2003.02811.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Real-time reverse-transcription polymerase chain reaction (RT-PCR) (qPCR) of the BCR-ABL mRNA is a suitable technique to measure the amount of circulating leukemic cells in chronic myelogenous leukemia (CML). In this study, we evaluated a BCR-ABL-specific qPCR method using the LightCycler technology in 95 patients with Philadelphia chromosome positive acute leukemia (n = 7) or CML in different stages (n = 88). Primers and hybridization probes were chosen to detect the most prevalent variants of BCR-ABL (b2a2, b3a2, b2a3, b3a3, e19a2, e1a2) with a sensitivity of 10(-5) for b2a2 and b3a2. With median BCR-ABL/G6PDH ratios of 10.7% in the untreated chronic phase, 43.2% in the newly diagnosed accelerated phase, and 131.4% in newly diagnosed blast crisis the BCR-ABL mRNA levels varied significantly between different stages of CML whereas no difference was found between blast crisis and untreated acute leukemias (136.9%). There was a strong relationship between qPCR results and cytogenetics in patients treated with imatinib, interferon-alpha, or following allografting. Thirteen patients with CML were sequentially examined by qPCR following myeloablative or non-myeloablative allogeneic peripheral blood stem cell transplantation. Five patients received donor lymphocytes and became BCR-ABL negative as confirmed by nested RT-PCR. The gradual disappearance of BCR-ABL positive cells could be monitored by qPCR following non-myeloablative transplantation. Comparison of BCR-ABL levels with the degree of donor chimerism showed that 91% of samples with complete donor chimerism were BCR-ABL negative. In 22% of BCR-ABL negative samples chimerism between 71% and 98% was observed, indicating the persistence of normal recipient's hematopoietic cells. In conclusion, the qPCR protocol used in this study is a reliable and fast method for monitoring molecular response in CML.
引用
收藏
页码:1 / 10
页数:10
相关论文
共 42 条
  • [1] Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8
    Andersen, MK
    Pedersen-Bjorgaard, J
    Kjeldsen, L
    Dufva, IH
    Brondum-Nielsen, K
    [J]. LEUKEMIA, 2002, 16 (07) : 1390 - 1393
  • [2] Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: Recommendations from a Workshop at the 2001 Tandem Meetings
    Antin, JH
    Childs, R
    Filipovich, AH
    Giralt, S
    Mackinnon, S
    Spitzer, T
    Weisdorf, D
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2001, 7 (09) : 473 - 485
  • [3] Branford S, 1999, BRIT J HAEMATOL, V107, P587
  • [4] Cervantes F, 1996, EUR J HAEMATOL, V57, P286
  • [5] MINIMAL RESIDUAL DISEASE AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOID-LEUKEMIA IN 1ST CHRONIC PHASE - CORRELATIONS WITH ACUTE GRAFT-VERSUS-HOST DISEASE AND RELAPSE
    CROSS, NCP
    HUGHES, TP
    FENG, L
    OSHEA, P
    BUNGEY, J
    MARKS, DI
    FERRANT, A
    MARTIAT, P
    GOLDMAN, JM
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1993, 84 (01) : 67 - 74
  • [6] CROSS NCP, 1994, LEUKEMIA, V8, P186
  • [7] CROSS NCP, 1993, BLOOD, V82, P1929
  • [8] Monitoring of residual disease and guided donor leucocyte infusion after allogeneic bone marrow transplantation by chimaerism analysis with short tandem repeats
    de Weger, RA
    Tilanus, MGJ
    Scheidel, KC
    van den Tweel, JG
    Verdonck, LF
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2000, 110 (03) : 647 - 653
  • [9] The molecular biology of chronic myeloid leukemia
    Deininger, MWN
    Goldman, JM
    Melo, JV
    [J]. BLOOD, 2000, 96 (10) : 3343 - 3356
  • [10] The risk of residual molecular and cytogenetic disease in patients with Philadelphia-chromosome positive first chronic phase chronic myelogenous leukemia is reduced after transplantation of allogeneic peripheral blood stem cells compared with bone marrow
    Elmaagacli, AH
    Beelen, DW
    Opalka, B
    Seeber, S
    Schaefer, UW
    [J]. BLOOD, 1999, 94 (02) : 384 - 389